This systematic review identified various bioactive compounds which have the potential to
serve as novel drugs or leads against acute myeloid leukemia. Acute myeloid leukemia …

Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …

Initially regarded as “epigenetic modifiers” acting predominantly through chromatin
remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase …

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and
progression. As promising anticancer targets, HDACs have gained a great deal of research …

Various human malignancies are characterized by excessive activation of the Janus family
of cytoplasmic tyrosine kinases (JAK) and their associated transcription factors STAT3 and …

Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …

Epigenetic inactivation of pivotal genes involved in correct cell growth is a hallmark of
human pathologies, in particular cancer. These epigenetic mechanisms, including crosstalk …

Despite the encouraging clinical progress of chemotherapeutic agents in cancer treatment,
innovation and development of new effective anticancer candidates still represents a …

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …

Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …